GLP-1 video reviews

A patient documents twelve months on Wegovy, covering titration timing, side effects, and weight outcomes.

• Real-world loss aligned with STEP-1 trial averages (~18% at maintenance)
• High protein + hydration significantly reduced nausea
• Stalls at month 4 and month 9 resolved on their own

Our take: Honest, methodical 12-month review — one of the most representative Wegovy timelines we have found for a typical insured patient.

A board-certified endocrinologist walks through Wegovy mechanism of action, titration protocol, and patient-selection criteria.

• Semaglutide half-life ~7 days enables weekly dosing
• Wegovy = Ozempic molecule at a 2.4 mg ceiling (vs 2.0 mg)
• Fast titration is the #1 predictor of GI dropout

Our take: Clear, evidence-anchored explainer — appropriate as a patient pre-prescription primer.

A patient breaks down the lesser-discussed Wegovy side effects beyond nausea — hair shedding, taste changes, and mood shifts.

• Telogen effluvium (temporary hair shedding) is common around month 3-4
• Taste preferences can shift — many report aversion to sweet foods
• Mood/affect changes reported anecdotally — discuss with provider

Our take: Useful framing of secondary effects most clinical literature undersells.

Comparison of Wegovy vs Ozempic for weight loss — same molecule, different indication, very different insurance treatment.

• Same molecule (semaglutide), different FDA indication
• Wegovy = weight-management coverage path; Ozempic = T2D path
• Off-label Ozempic for weight loss is increasingly denied by PBMs

Our take: Best video we have found for understanding the insurance + prior-auth dynamics between the two.

Clinical breakdown of the STEP-1 trial that supported Wegovy approval — what the 15% mean weight loss represents and what it does not.

• STEP-1: 68 weeks, n=1961, 15% mean weight loss vs 2.4% placebo
• One-third of completers lost ≥20% body weight
• Discontinuation rate ~7% for GI adverse events

Our take: The cleanest layperson-grade walkthrough of the STEP-1 dataset we have seen.

A T2D patient documents six months on Ozempic — HbA1c trajectory, weight loss, and fasting glucose changes.

• HbA1c dropped from 8.4 → 6.2 over 6 months
• Fasting glucose normalized within 8 weeks of starting
• Weight loss ~14% — secondary to glycemic improvement

Our take: A textbook T2D Ozempic response — strong educational value for newly diagnosed viewers.

A retail pharmacist walks through the practical details of starting Ozempic — pen storage, injection technique, dose escalation.

• Refrigerate unopened pens; once opened, room temp ≤56 days
• Rotate injection sites: abdomen, thigh, upper arm
• Always use a new needle — do not reuse

Our take: Practical, no-nonsense pharmacist walkthrough — bookmark-worthy for any first-time injector.

News explainer covering the resolved 2024 Ozempic shortage, what triggered it, and how to prepare for any future supply disruption.

• Ozempic removed from FDA shortage list December 2024
• Supply normalization expected to hold through 2025+
• Compounded semaglutide phase-out triggered by shortage resolution

Our take: Tight, accurate news roundup — use as a reference point if patients ask about supply concerns.

Internist discusses off-label Ozempic prescribing for weight loss, prior-auth realities, and when to switch to Wegovy.

• Off-label is legal but commercial insurance increasingly denies
• Cash-pay route is rarely cost-effective vs compounded options
• BMI ≥30 (or ≥27 with comorbidity) → switch to Wegovy is appropriate

Our take: Refreshingly candid from a practicing physician — useful framing for patients navigating denials.

Long-form one-year retrospective on Ozempic for combined T2D + weight management, including the parts the creator wishes they had known.

• Plateau at month 7 broke after strength training was added
• Resting heart rate increased ~6 bpm — discussed with cardiology
• Loose skin became a reality past 15% loss — manage expectations

Our take: Mature, balanced one-year reflection — the kind of context most short-form content misses.

Patient testimonial covering six months on Mounjaro, with attention to titration cadence and protein habits that supported lean-mass retention.

• Lost 45 lbs in 6 months — front-loaded in months 2-4
• Stuck on each titration step for 6 weeks (not 4) to ease GI
• 120-140 g protein/day preserved muscle per DEXA scan

Our take: Strong real-world case with measurable outcomes — DEXA verification is a nice touch.

Educational deep-dive on why tirzepatide outperforms pure GLP-1 agonists in head-to-head trials — the GIP angle.

• Tirzepatide co-activates GIP + GLP-1 receptors (dual agonism)
• GIP arm appears to enhance lipid handling + insulin sensitivity
• SURMOUNT-1 head-to-head: tirzepatide outperformed semaglutide

Our take: Best explainer we have found on why tirzepatide hits harder than semaglutide.

A nurse practitioner walks through expected vs concerning side effects on Mounjaro, with clear escalation criteria.

• Mild-moderate nausea + bloating: expected, usually self-resolves
• Severe upper-abdominal pain → suspect pancreatitis, seek care
• Persistent vomiting >24h → dehydration risk, contact provider

Our take: Clear escalation thresholds — exactly the framework patients need on day one.

Clinical review of the SURPASS-2 trial comparing tirzepatide and semaglutide for T2D outcomes.

• SURPASS-2: tirzepatide 15 mg vs semaglutide 1 mg head-to-head
• HbA1c reduction: tirzepatide -2.30% vs semaglutide -1.86%
• Weight loss: tirzepatide -11.2 kg vs semaglutide -5.7 kg

Our take: Crisp, well-cited walkthrough of the trial that reshaped clinical GLP-1 prescribing.

News + how-to walkthrough on appealing a Mounjaro denial, including appeal letter templates.

• Most denials stem from missing diagnosis code or PA paperwork
• External appeal success rates are ~50% with full documentation
• Letters of medical necessity carry significant weight

Our take: Practical playbook — pair with our coverage + provider tools.

Patient diary covering the first 90 days on Zepbound — titration symptoms, weight trajectory, and meal-pattern shifts.

• First 4 weeks at 2.5 mg: mild nausea + early satiety
• Weeks 5-8 at 5 mg: appetite suppression dominant
• Lost 18 lbs in 90 days — front-loaded in weeks 4-10

Our take: Useful early-stage timeline for anyone deciding whether to start.

Explainer on the December 2024 FDA approval of Zepbound for obstructive sleep apnea, including SURMOUNT-OSA trial highlights.

• First GLP-1 approved for moderate-severe OSA in obese adults
• SURMOUNT-OSA: AHI reduction up to 63% vs placebo
• May reduce or eliminate CPAP dependence in some patients

Our take: Important update — Zepbound is now a legitimate OSA-coverage path.

Side-by-side comparison of Zepbound and Wegovy across efficacy, side effects, cost, and access.

• Efficacy: Zepbound averages slightly higher mean weight loss
• Side effects: broadly similar GI profile across both
• Cost: comparable list price; coverage varies wildly by plan

Our take: Fair, balanced comparison — recommended for patients weighing the two.

Walkthrough of the single-dose vial format vs the auto-injector pen — why the vial costs less and how to use it safely.

• Vials sold direct via LillyDirect at a steep discount vs pens
• Vial requires syringe + needle (provided in the kit)
• Vial format limited to 2.5 mg and 5 mg starter doses

Our take: Hands-on vial walkthrough — essential viewing for anyone using LillyDirect direct-to-consumer pricing.

Obesity medicine specialist gives a candid take on patient selection for Zepbound — who benefits most, who should skip it.

• Best fit: BMI ≥30 with metabolic comorbidity + treatment plan in place
• Poor fit: history of pancreatitis, severe gastroparesis, MEN2/MTC
• Pregnancy: discontinue ≥2 months before planned conception

Our take: Honest, patient-first framing — exactly the second opinion most viewers need before starting.

A patient documents twelve months on Wegovy, covering titration timing, side effects, and weight outcomes.

• Real-world loss aligned with STEP-1 trial averages (~18% at maintenance)
• High protein + hydration significantly reduced nausea
• Stalls at month 4 and month 9 resolved on their own

Our take: Honest, methodical 12-month review — one of the most representative Wegovy timelines we have found for a typical insured patient.

A patient breaks down the lesser-discussed Wegovy side effects beyond nausea — hair shedding, taste changes, and mood shifts.

• Telogen effluvium (temporary hair shedding) is common around month 3-4
• Taste preferences can shift — many report aversion to sweet foods
• Mood/affect changes reported anecdotally — discuss with provider

Our take: Useful framing of secondary effects most clinical literature undersells.

A T2D patient documents six months on Ozempic — HbA1c trajectory, weight loss, and fasting glucose changes.

• HbA1c dropped from 8.4 → 6.2 over 6 months
• Fasting glucose normalized within 8 weeks of starting
• Weight loss ~14% — secondary to glycemic improvement

Our take: A textbook T2D Ozempic response — strong educational value for newly diagnosed viewers.

Long-form one-year retrospective on Ozempic for combined T2D + weight management, including the parts the creator wishes they had known.

• Plateau at month 7 broke after strength training was added
• Resting heart rate increased ~6 bpm — discussed with cardiology
• Loose skin became a reality past 15% loss — manage expectations

Our take: Mature, balanced one-year reflection — the kind of context most short-form content misses.

Patient testimonial covering six months on Mounjaro, with attention to titration cadence and protein habits that supported lean-mass retention.

• Lost 45 lbs in 6 months — front-loaded in months 2-4
• Stuck on each titration step for 6 weeks (not 4) to ease GI
• 120-140 g protein/day preserved muscle per DEXA scan

Our take: Strong real-world case with measurable outcomes — DEXA verification is a nice touch.

Patient diary covering the first 90 days on Zepbound — titration symptoms, weight trajectory, and meal-pattern shifts.

• First 4 weeks at 2.5 mg: mild nausea + early satiety
• Weeks 5-8 at 5 mg: appetite suppression dominant
• Lost 18 lbs in 90 days — front-loaded in weeks 4-10

Our take: Useful early-stage timeline for anyone deciding whether to start.

A board-certified endocrinologist walks through Wegovy mechanism of action, titration protocol, and patient-selection criteria.

• Semaglutide half-life ~7 days enables weekly dosing
• Wegovy = Ozempic molecule at a 2.4 mg ceiling (vs 2.0 mg)
• Fast titration is the #1 predictor of GI dropout

Our take: Clear, evidence-anchored explainer — appropriate as a patient pre-prescription primer.

A retail pharmacist walks through the practical details of starting Ozempic — pen storage, injection technique, dose escalation.

• Refrigerate unopened pens; once opened, room temp ≤56 days
• Rotate injection sites: abdomen, thigh, upper arm
• Always use a new needle — do not reuse

Our take: Practical, no-nonsense pharmacist walkthrough — bookmark-worthy for any first-time injector.

Educational deep-dive on why tirzepatide outperforms pure GLP-1 agonists in head-to-head trials — the GIP angle.

• Tirzepatide co-activates GIP + GLP-1 receptors (dual agonism)
• GIP arm appears to enhance lipid handling + insulin sensitivity
• SURMOUNT-1 head-to-head: tirzepatide outperformed semaglutide

Our take: Best explainer we have found on why tirzepatide hits harder than semaglutide.

A nurse practitioner walks through expected vs concerning side effects on Mounjaro, with clear escalation criteria.

• Mild-moderate nausea + bloating: expected, usually self-resolves
• Severe upper-abdominal pain → suspect pancreatitis, seek care
• Persistent vomiting >24h → dehydration risk, contact provider

Our take: Clear escalation thresholds — exactly the framework patients need on day one.

Walkthrough of the single-dose vial format vs the auto-injector pen — why the vial costs less and how to use it safely.

• Vials sold direct via LillyDirect at a steep discount vs pens
• Vial requires syringe + needle (provided in the kit)
• Vial format limited to 2.5 mg and 5 mg starter doses

Our take: Hands-on vial walkthrough — essential viewing for anyone using LillyDirect direct-to-consumer pricing.

Comparison of Wegovy vs Ozempic for weight loss — same molecule, different indication, very different insurance treatment.

• Same molecule (semaglutide), different FDA indication
• Wegovy = weight-management coverage path; Ozempic = T2D path
• Off-label Ozempic for weight loss is increasingly denied by PBMs

Our take: Best video we have found for understanding the insurance + prior-auth dynamics between the two.

Clinical breakdown of the STEP-1 trial that supported Wegovy approval — what the 15% mean weight loss represents and what it does not.

• STEP-1: 68 weeks, n=1961, 15% mean weight loss vs 2.4% placebo
• One-third of completers lost ≥20% body weight
• Discontinuation rate ~7% for GI adverse events

Our take: The cleanest layperson-grade walkthrough of the STEP-1 dataset we have seen.

Internist discusses off-label Ozempic prescribing for weight loss, prior-auth realities, and when to switch to Wegovy.

• Off-label is legal but commercial insurance increasingly denies
• Cash-pay route is rarely cost-effective vs compounded options
• BMI ≥30 (or ≥27 with comorbidity) → switch to Wegovy is appropriate

Our take: Refreshingly candid from a practicing physician — useful framing for patients navigating denials.

Clinical review of the SURPASS-2 trial comparing tirzepatide and semaglutide for T2D outcomes.

• SURPASS-2: tirzepatide 15 mg vs semaglutide 1 mg head-to-head
• HbA1c reduction: tirzepatide -2.30% vs semaglutide -1.86%
• Weight loss: tirzepatide -11.2 kg vs semaglutide -5.7 kg

Our take: Crisp, well-cited walkthrough of the trial that reshaped clinical GLP-1 prescribing.

Side-by-side comparison of Zepbound and Wegovy across efficacy, side effects, cost, and access.

• Efficacy: Zepbound averages slightly higher mean weight loss
• Side effects: broadly similar GI profile across both
• Cost: comparable list price; coverage varies wildly by plan

Our take: Fair, balanced comparison — recommended for patients weighing the two.

Obesity medicine specialist gives a candid take on patient selection for Zepbound — who benefits most, who should skip it.

• Best fit: BMI ≥30 with metabolic comorbidity + treatment plan in place
• Poor fit: history of pancreatitis, severe gastroparesis, MEN2/MTC
• Pregnancy: discontinue ≥2 months before planned conception

Our take: Honest, patient-first framing — exactly the second opinion most viewers need before starting.

News explainer covering the resolved 2024 Ozempic shortage, what triggered it, and how to prepare for any future supply disruption.

• Ozempic removed from FDA shortage list December 2024
• Supply normalization expected to hold through 2025+
• Compounded semaglutide phase-out triggered by shortage resolution

Our take: Tight, accurate news roundup — use as a reference point if patients ask about supply concerns.

News + how-to walkthrough on appealing a Mounjaro denial, including appeal letter templates.

• Most denials stem from missing diagnosis code or PA paperwork
• External appeal success rates are ~50% with full documentation
• Letters of medical necessity carry significant weight

Our take: Practical playbook — pair with our coverage + provider tools.

Explainer on the December 2024 FDA approval of Zepbound for obstructive sleep apnea, including SURMOUNT-OSA trial highlights.

• First GLP-1 approved for moderate-severe OSA in obese adults
• SURMOUNT-OSA: AHI reduction up to 63% vs placebo
• May reduce or eliminate CPAP dependence in some patients

Our take: Important update — Zepbound is now a legitimate OSA-coverage path.